Comparative Pharmacology
Head-to-head clinical analysis: RIMANTADINE HYDROCHLORIDE versus VITRAVENE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RIMANTADINE HYDROCHLORIDE versus VITRAVENE PRESERVATIVE FREE.
RIMANTADINE HYDROCHLORIDE vs VITRAVENE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Rimantadine is a tricyclic amine antiviral that inhibits influenza A virus replication by blocking the M2 proton ion channel, preventing viral uncoating and release of viral RNA into host cells.
Antisense oligonucleotide that binds to mRNA of human cytomegalovirus (HCMV), inhibiting viral replication by blocking protein synthesis.
100 mg orally twice daily for 7 days; initiate within 48 hours of symptom onset.
Intravitreal injection: 330 mcg (0.05 mL of 6.6 mg/mL solution) every 2 weeks for 2 doses, then every 4 weeks.
None Documented
None Documented
25.4 hours (range 13–65 h); prolonged in elderly (38 h) and severe renal impairment (CrCl <10 mL/min: up to 130 h).
Terminal elimination half-life is approximately 2 hours in patients with normal renal function. In patients with renal impairment, half-life may be prolonged up to 10 hours.
Renal: 75% unchanged; fecal: <10%; biliary: minimal. Total clearance 2.5 mL/min/kg.
Primarily renal excretion. Approximately 40% of the dose is excreted unchanged in urine within 24 hours. Biliary/fecal excretion accounts for less than 5%.
Category A/B
Category C
Antiviral
Antiviral